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A B S T R A C T
Introduction: Whether menopause increases the risk of type 2 diabetes mellitus (T2DM) independently of ageing
has been a matter of debate. Controversy also exists about the beneﬁts and risks of menopausal hormone therapy
(MHT) in women with T2DM.
Aims: To summarise the evidence on 1) the eﬀect of menopause on metabolic parameters and the risk of T2DM,
2) the eﬀect of T2DM on age at menopause, 3) the eﬀect of MHT on the risk of T2DM, and 4) the management of
postmenopausal women with T2DM.
Materials and methods: Literature review and consensus of experts’ opinions.
Results and conclusion: Metabolic changes during the menopausal transition include an increase in and the
central redistribution of adipose tissue, as well as a decrease in energy expenditure. In addition, there is im-
pairment of insulin secretion and insulin sensitivity and an increase in the risk of T2DM. MHT has a favourable
eﬀect on glucose metabolism, both in women with and in women without T2DM, while it may delay the onset of
T2DM. MHT in women with T2DM should be administered according to their risk of cardiovascular disease
(CVD). In women with T2DM and low CVD risk, oral oestrogens may be preferred, while transdermal 17β-
oestradiol is preferred for women with T2DM and coexistent CVD risk factors, such as obesity. In any case, a
progestogen with neutral eﬀects on glucose metabolism should be used, such as progesterone, dydrogesterone or
transdermal norethisterone. Postmenopausal women with T2DM should be managed primarily with lifestyle
intervention, including diet and exercise. Most of them will eventually require pharmacological therapy. The
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selection of antidiabetic medications should be based on the patient’s speciﬁc characteristics and comorbidities,
as well on the metabolic, cardiovascular and bone eﬀects of the medications.
1. Introduction
Diabetes mellitus (DM) is a public health problem, especially in
developed countries. It aﬀects about 9.1% of the adult population in
Europe and 13.3% in the United States of America [1]. The greater
prevalence of DM in developed countries is broadly associated with
ageing of the population [2]. Between 2015 and 2030, the world po-
pulation aged over 60 years is projected to increase by 56%, from 901
million to 1.4 billion; by 2050 it is expected to reach nearly 2.1 billion
[3]. These data suggest that the number of postmenopausal women
with DM will grow substantially. The management of menopause in
women with type 2 diabetes mellitus (T2DM) is challenging, as the
precise nature of the risks and beneﬁts of menopausal hormone therapy
(MHT) in women with T2DM are still unclear.
The aim of this clinical guide is to summarise the evidence on 1) the
eﬀect of menopause on metabolic parameters and the risk of T2DM, 2)
the eﬀect of T2DM on age at menopause, 3) the eﬀect of MHT on the
risk of T2DM, and 4) the management of postmenopausal women with
T2DM.
2. Metabolic changes during the menopausal transition
Menopause is the permanent cessation of menses due to oocyte
depletion. The result is an abrupt decrease in endogenous oestradiol
(E2). During the transition to menopause, women undergo phenoty-
pical, metabolic and biochemical changes which increase the risk of
T2DM. Whether these changes are independent of ageing itself has been
a matter of debate [4].
Women gain weight during the menopausal transition. While this
may be inﬂuenced by age rather than menopause per se [5], the me-
nopausal transition is independently associated with an increase in fat
mass, especially in the abdominal region [6,7]. Perimenopausal
women, furthermore, undergo a decrease in lean body mass and a
signiﬁcant reduction in energy expenditure, mainly from fat oxidation,
which favour an increase in total body and visceral fat, without major
changes in energy intake [6,7]. Visceral adiposity augments the pro-
duction of proinﬂammatory cytokines, increases circulating free fatty
acids and promotes the generation of reactive oxygen species, con-
tributing to the development of insulin resistance [8]. On the other
hand, menopause is a state of relative androgen excess: the post-
menopausal ovary continues to secrete androgens, with higher bioa-
vailability, due to the decrease in sex hormone-binding globulin (SHBG)
seen during the transition. These hormonal changes further increase
insulin resistance [9]. The prevalence of the metabolic syndrome,
therefore, increases steeply after menopause, to between 30% and 70%,
compared with 14–45% in women of reproductive age [8,10]. The
metabolic syndrome has its pathogenetic origin in insulin resistance
and is characterised by abnormal glucose metabolism, hypertension,
central obesity and dyslipidaemia [11–14].
Beyond the metabolic changes triggered by menopause, experi-
mental studies suggest that decreased E2 concentrations, as well as
decreased oestrogen receptor-α (ERα) activity, can cause insulin re-
sistance in peripheral tissues [15,16]. Pancreatic β-cells have to com-
pensate for insulin resistance to maintain glucose homeostasis; only
when β-cell dysfunction coexists with insulin resistance does T2DM
ultimately develop. Animal studies suggest an adverse eﬀect of hypo-
gonadism on insulin secretion. Ovariectomised rodents consistently
present impaired β-cell function, while decreased E2 action via ERα and
ERβ seem to aﬀect the survival of β-cells and the secretion of insulin,
respectively [17–19].
3. Eﬀect of menopause on the incidence of T2DM
Given the adverse metabolic changes associated with the meno-
pausal transition, menopause is associated with an increased risk of
T2DM. The Study of Women’s Health Across the Nation (SWAN) sug-
gested that lower E2 concentrations resulted in a 47% higher risk of
T2DM during the menopausal transition [20]. This ﬁnding was diﬀerent
from the initial results, which had suggested that the glucose dysre-
gulation observed during menopause was associated with age and not
with the decline of ovarian function [21,22]. Furthermore, the Eur-
opean Prospective Investigation into Cancer (EPIC)-InterAct, after fol-
lowing women for 11 years, showed that menopause before the age of
40 years was associated with a 32% greater risk of T2DM [23]. Another
observational study, from China, provided evidence that menopause
before the age of 45 years was associated with a 20% greater risk of
T2DM compared with the average age of menopause [24]. In ac-
cordance with these ﬁndings, studies in women after ovariectomy have
reported that their risk of T2DM is up to 57% higher than for women
who have not undergone ovariectomy [25,26]. A recent analysis of data
from the Women's Health Initiative (WHI) study, examining 124,379
postmenopausal women, concluded that women with a reproductive
lifetime (diﬀerence between age at menarche and age at last period) of
less than 30 years had a 37% higher risk of T2DM than women with a
reproductive lifetime of 36–40 years. These results were reached after
adjustment for chronological age [27]. Data from the same population
showed that the report of any climacteric symptom was associated with
an 18% increase in the incidence of T2DM (hazard ratio (HR) 1.18, 95%
conﬁdence interval (CI) 1.14–1.22). The risk increased in parallel with
the severity and duration of symptoms, independent of obesity [28].
4. Eﬀect of DM on age at menopause
Several studies have indicated an earlier age at menopause in
women with type 1 diabetes mellitus (T1DM) than for women without
T1DM. The prevalence of premature ovarian insuﬃciency in patients
with T1DM is also higher, which might be related to the fact that both
conditions are associated with autoimmunity [29,30]. The Familial
Autoimmune and Diabetes study showed that women with T1DM ex-
perienced menopause at an earlier age (41.6 years) than their sisters (at
age 49.9) or unrelated controls without diabetes (at age 48 years) [29].
Similarly, the European Prospective Investigation into Cancer and Nu-
trition (a cohort study) found that onset of diabetes before the age of 20
was associated with menopause at a younger age [30].
In contrast, other studies do not support an eﬀect of diabetes on age
at menopause. In the Ovarian Ageing in type 1 Diabetes mellitus
(OVADIA) study, age at menopause was similar for women with and
without the disease (49.8 years) [31]. Similarly, the results of the
Epidemiology of Diabetes Interventions and Complications (EDIC)
study, which is a follow-up of the Diabetes Control and Complication
Trial (DCCT), reported that age at menopause was not related to the
therapy regimen or glycaemic control [32]. In a large population-based
Finnish study of women with childhood-onset diabetes, the median age
at menopause in the patient group was similar to that in the general
population. Only the presence of advanced microvascular complica-
tions, such as renal disease and proliferative retinopathy, was asso-
ciated with earlier menopause [33].
Furthermore, T2DM may accelerate the onset of menopause [30]. A
study of 6079 middle-aged women from 11 Latin American countries
showed that the proportion of middle-aged women with T2DM who had
been through the menopause was three times that in the women
without T2DM [34]. Moreover, women with a later onset of T2DM
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(over 50 years) tended to have a later age of menopause, but this could
have been associated with their higher body mass index (BMI) [34].
5. Impact of MHT on the risk of T2DM
MHT has a beneﬁcial eﬀect on various metabolic parameters, in-
cluding a decrease in abdominal fat deposition, an increase in lipid
oxidation and enhancement of energy expenditure [35,36]. Evidence
also suggests that oestrogens improve insulin sensitivity through a di-
rect eﬀect on ERs in liver, muscle and adipose tissue [37,38]. Studies in
rodents have shown that oestrogens may augment insulin secretion in
pancreatic β-cells too [17].
A large body of evidence indicates that MHT reduces the risk of
T2DM. The incidence of T2DM in the MHT arm was reduced by 35% in
the Heart and Estrogen/progestin Replacement Study (HERS) [39], and
by 21% in the Women’s Health Initiative (WHI) study [40]. The same
eﬀect was reported in two prospective observational studies, the
Nurses’ Health Study (NHS), where the use of MHT resulted in a 20%
reduction in the incidence of T2DM [41], and the Etude Epidémiolo-
gique de Femmes de la Mutuelle Générale de l’Education Nationale
(E3N), where the incidence of T2DM was 25% lower in women on MHT
[42]. A meta-analysis of 107 trials showed that MHT reduced insulin
resistance by 13% and new-onset T2DM by 30% [43].
Most large trials have assessed women on treatment with con-
jugated equine oestrogens (CEE) combined with medroxyprogesterone
acetate (MPA); there are limited data regarding other types of MHT.
Among the E3N cohort of 63,624 postmenopausal women, 1220 new-
onset T2DM cases were identiﬁed, and the use of oral MHT was asso-
ciated with a lower risk of new-onset T2DM than the use of transdermal
MHT [42]. Because of the ﬁrst-pass metabolism in the liver, oral CEE
has stronger beneﬁcial eﬀects on insulin resistance, suppression of he-
patic glucose production and cholesterol concentrations [43,44].
However, CEE increases the hepatic synthesis of triglycerides, C-re-
active protein (CRP) and coagulation factors, and may increase the risk
of thrombosis [45]. Furthermore, progestogens have been associated
with the development of insulin resistance; in most trials, the beneﬁcial
eﬀects of oestrogens were decreased by the addition of a progestogen,
in a dose-dependent manner. Progesterone, norethisterone acetate
(NETA) and dydrogesterone are likely to be more neutral than MPA and
levonorgestrel, which are more androgenic [46–51].
6. MHT in women with T2DM
In women with T2DM, MHT improves glycaemia, insulin resistance
and other components of the metabolic syndrome [43]. Despite this, the
frequency of MHT use among women with T2DM is about 50% lower
than in the general population. This is probably because T2DM was
broadly considered in the past to be a CVD equivalent [52], and this
rationale still deters many clinicians from prescribing MHT to patients
with T2DM. However, given the beneﬁcial eﬀects of MHT on glycaemic
control, an individualised approach in treating menopausal symptoms
should be considered. Women with T2DM may be excellent candidates
for MHT, after careful evaluation of their CVD risk [35,53–55]. In peri-
or recently postmenopausal women with T2DM and low CVD risk, oral
oestrogens may be preferred. In obese women with T2DM or in any
woman at moderate risk of CVD, transdermal 17β-oestradiol is the
preferred treatment. In any case, a progestogen with minimal eﬀects on
glucose metabolism should be used, like progesterone, dydrogesterone
or transdermal norethisterone [35,53–56].
7. Management of T2DM in women during and after menopause
Many of the adverse metabolic consequences of the menopause can
be countered by lifestyle changes, such as optimal diet, increase in
physical activity, cessation of smoking and decrease in alcohol con-
sumption. Lifestyle intervention should be the cornerstone of
management in women with T2DM entering the menopause. Weight
loss is very important, not only for the treatment of T2DM but also for
its prevention [57]. However, as bone health and sarcopenia are im-
portant concerns during the postmenopausal period, only gradual and
modest weight loss (5–7% of initial body weight annually) should be
recommended [58,59]. Speciﬁc clinical nutritional recommendations
include consumption of mono- and polyunsaturated fat rather than
saturated forms, reduction in the total amount of carbohydrates and a
preference for those deriving from fruits and whole grains, as well as
protein intake being mainly from ﬁsh, poultry or skimmed dairy pro-
ducts. Nutrition programmes that provide 1200–1500 kcal/day or that
create an energy deﬁcit of 500–750 kcal/day can result in the desired
weight loss. Consumption of nuts and seeds, appropriate intake of cal-
cium and vitamin D, and low intakes of alcohol and sodium are addi-
tional crucial dietary changes. The recommended calcium and vitamin
D daily intakes for women older than 50 years with a risk of fracture are
1000–1200mg and 600–800 IU, respectively [58–62].
Physical exercise prevents weight gain and muscle atrophy, and
improves bone quality and glycaemic ontrol. Women with T2DM
should be encouraged to engage in regular aerobic physical activity – at
least 150min per week of moderate exercise or at least 75min of vig-
orous exercise per week. Anaerobic activities targeting major muscle
groups should also be performed. Physical activity increases muscle
mass and because muscle is denser than fat it may limit weight loss
despite fat reduction. In that case, women should be informed that this
is still excellent for their health and the indicator to be checked should
then be waist circumference [57,60].
Smoking represents an important risk factor for many diseases as-
sociated with menopause and ageing, such as CVD, osteoporosis and
cancer. Therefore, smoking discontinuation should be an essential part
of routine clinical consultation [60].
Most postmenopausal women with T2DM will eventually require
pharmacological therapy. Metformin, sulfonylureas, thiazolidinediones
(TZDs), dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like pep-
tide-1 receptor agonists (GLP-1RA), sodium-dependent glucose trans-
porter-2 inhibitors (SGLT-2i) and insulin are the most commonly used
medications. They have diﬀerent metabolic, cardiovascular and bone
eﬀects [63–65], and the most suitable agent for any particular woman
should be selected according to these diﬀerent eﬀects after taking into
consideration the woman’s speciﬁc characteristics and comorbidities.
Metformin should be used as the ﬁrst-line treatment, while DPP-4i and
GLP-1RA may be useful second-line options because of their beneﬁcial
(or at least neutral) eﬀects on bones. TZDs should be avoided in women
with osteoporosis and increased fracture risk, as should canagliﬂozin,
an SGLT-2i; other SGLT-2i are not well-validated options [58,63–65].
8. Conclusions
Menopause is associated with an adverse metabolic proﬁle and
possibly an increase in T2DM risk. MHT has a favourable eﬀect on
glucose homeostasis both in women with and in women without T2DM.
Women with T2DM can receive MHT after careful assessment of their
CVD risk. They should also be managed with lifestyle interventions,
including diet, exercise, smoking cessation and decrease in alcohol
consumption, with a combined focus on metabolic, cardiovascular and
bone health. The most suitable antidiabetic agents should be selected
according to the individual’s cardiometabolic and fracture risk.
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